Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

• Matt Stevenson,
• Rachel Archer,
• Jon Tosh,
• Emma Simpson,
• Emma Everson-Hock,
• John Stevens,
• Monica Hernandez-Alava,
• Suzy Paisley,
• Kath Dickinson,
• David Scott,
• Adam Young,
• Allan Wailoo

Affiliations

Matt Stevenson

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Rachel Archer

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Jon Tosh

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Emma Simpson

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Emma Everson-Hock

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

John Stevens

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Monica Hernandez-Alava

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Suzy Paisley

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Kath Dickinson

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

David Scott

Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK

Adam Young

Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK

Allan Wailoo

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK